glp-1 oral medications FDA Grants Speedy Approval to Eli Lilly's RA Drug for Obesity Oral GLP-1 for Weight Loss:

van der Pluijm I, Burger J, van Heijningen PM, Ijpma A, van Vliet N, Milanese C, et al

115-271), enacted on October 24, 2018

Introduction Cagrilintide is a long-acting, acylated analog of human amylin developed by Novo Nordisk and investigated as an amylin- and calcitonin-receptor agonist

*Correspondence: Lin Wang, [email protected] This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Tirzepatide for managing overweight and obesity